Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence
Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu
Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu
View: Text | PDF
Research Article Cell biology Oncology

Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence

  • Text
  • PDF
Abstract

Chordomas are rare malignant osseous neoplasms with a striking rate of recurrence. Primary chordomas typically originate from embryonic notochord remnants, whereas recurrent chordomas usually stem from tumor cells infiltrating bone or cartilage after surgery. Clinically, the recurrent chordomas exhibit a stiffer extracellular microenvironment (ECM) than primary tumors. Intriguingly, this study identified cytoskeleton rearrangement, stress fiber reorganization, enhanced stemness, and Notch signaling activation in recurrent chordoma tissues or cell lines surviving stiff substrates, indicating the critical roles of mechanical remodeling and tumor stemness in stiffness resistance. We propose a potentially novel recurrence model where tumor cells experience mechanoadaptive organization, which enables them to resist stiff microenvironment-induced cell death. O-GlcNAcylation of Notch1 intracellular domain (NICD1) is central to this process. Mechanistically, the stiff ECM-driven ligand-independent phosphorylation of EPHA2 sequentially activated LYN kinase and subsequently triggered O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) activity by phosphorylating Y989 and Y418, critical residues for OGT glycosyltransferase activity; this induced NICD1 O-GlcNAcylation at T2063, T2090, and S2162, specifically promoting transcription of mechanical and stemness-related genes. MIR31 deletion upregulated LYN, enhancing stiffness perception and promoting O-GlcNAc addition to NICD1, finally resulting in mechanoadaptation- and tumor stemness–driven recurrence. Consequently, MIR31 deletion is a potential biomarker for recurrence and patient stratification in Notch- or OGT-targeted therapies.

Authors

Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu

×

Figure 5

Activation of LYN in response to stiff ECM mediates NICD1 O-GlcNAcylation by facilitating OGT catalytic activity.

Options: View larger image (or click on image) Download as PowerPoint
Activation of LYN in response to stiff ECM mediates NICD1 O-GlcNAcylatio...
(A) Dual luciferase reporter to assess Notch signaling activity in MUG-Chor1 cells cultured on substrates with different stiffnesses. (B) IP determined the effect of increased stiffness on NICD1 O-GlcNAcylation. (C) Expression of genes regulated by increased stiffness was assessed by qRT-PCR in primary and recurrent chordoma tissues, including HES1, HES5, HEY1, HEY2, NRARP, MYC, NANOG, OCT4, VCL, and SOX2. The orange dotted line indicates a fold change of 1. (D) IP was used to determine tyrosine phosphorylation of OGT. MLR-1023 (10 μM, 24 hours) was used to activate LYN tyrosine kinase, while bafetinib (10 nM, 24 hours) was utilized to inhibit LYN tyrosine kinase activity. (E) IP was used to identify tyrosine, serine, and threonine phosphorylation of WT and Y418A/Y989A OGT. (F and G) UDP-Glo Glycosyltransferase Assay (Promega) was used to detect glycosyltransferase enzyme activity of WT and mutant OGT. In F, symbols indicate significant differences versus specified groups: *WT; #Y418A; $Y989A. (H and I) IP was used to assess NICD1 O-GlcNAcylation in cells ectopically expressing WT or mutant OGT with or without LYN overexpression. (J) Effects of WT or mutant OGT with or without LYN overexpression on nuclear and cytoplasmic location of NICD1 protein were determined. (K) Whether O-GlcNAcylation inhibitor could abrogate effects of LYN overexpression on half-lives of NICD1 and whether mutation of OGT Y418/Y989 could cancel effects of WT OGT and LYN overexpression on half-lives of NICD1 were both assessed using WB. Quantification of Supplemental Figure 7, K and L. (L–N) Effects of LYN overexpression, kinase activation, or kinase activity suppression on F-actin, VCL, focal adhesions (L); COL1A1 (M); and cellular contractility (N) were assessed. Scale bar: 10 μm (L); 50 μm (M). (O) Effects of LYN overexpression, kinase activation, or kinase activity suppression on resistance to high stiffness– or stress-induced cell death were determined. (P) Duolink PLA to detect OGT-specific tyrosine phosphorylation in paired primary and recurrent chordoma tissues. Scale bar: 50 μm. (Q) In chordoma cells with NICD1 knockout, the collagen cell contraction assay was performed to assess effects of WT or T2063A/T2090A/S2162A (MT) NICD1 with or without LYN overexpression on MUG-Chor1 cellular contractility. Data in A, F, G, N, O, and Q are presented as mean ± SD. Statistical analysis was performed using 1-way ANOVA (A, F, G, N, O, and Q). *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts